Innovator International Developed Power Buffer ETF - November (INOV)
- Previous Close
27.78 - Open
27.79 - Bid --
- Ask --
- Day's Range
28.00 - 28.00 - 52 Week Range
24.97 - 28.05 - Volume
0 - Avg. Volume
703 - Net Assets 2.76M
- NAV 27.96
- PE Ratio (TTM) --
- Yield --
- YTD Daily Total Return 3.57%
- Beta (5Y Monthly) 0.00
- Expense Ratio (net) 0.85%
The fund invests at least 80% of its net assets in FLexible EXchange® Options that reference the iShares MSCI EAFE ETF. FLEX Options are exchange-traded option contracts with uniquely customizable terms. It's strategy has been specifically designed to produce the outcomes based upon the performance of the underlying ETF’s share price over the duration of the outcome period. The fund is non-diversified.
Innovator ETFs
Fund Family
Options Trading
Fund Category
2.76M
Net Assets
2023-10-31
Inception Date
Performance Overview: INOV
Trailing returns as of 5/3/2024. Category is Options Trading.
People Also Watch
Holdings: INOV
Sector Weightings
Related ETF News
Research Reports: INOV
Analyst Report: LivaNova PLC
UK-based LivaNova was born of a combination between Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiovascular and cardiopulmonary solutions (with surgical heart valves, heart-lung machines, and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management and heart valve businesses. It derives roughly half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.
RatingPrice TargetAnalyst Report: LivaNova PLC
UK-based LivaNova was born of a combination between Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiovascular and cardiopulmonary solutions (with surgical heart valves, heart-lung machines, and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management and heart valve businesses. It derives roughly half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.
RatingPrice TargetPINC: Lowering target price to $22.00
PREMIER INC-CLASS A has an Investment Rating of HOLD; a target price of $22.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.
RatingPrice TargetPINC: Raising target price to $23.00
PREMIER INC-CLASS A has an Investment Rating of HOLD; a target price of $23.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.
RatingPrice Target